Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks mitochondrial electron transport in the malaria parasite, halting ATP production, while proguanil is converted to cycloguanil, which inhibits the parasite's dihydrofolate reductase enzyme. The dual action disrupts parasite metabolism and replication, leading to rapid parasite clearance.

The specific dose of Malarone is determined by the prescribing healthcare professional based on factors such as the indication, patient weight, age, renal and hepatic function, and travel itinerary. Patients should follow the prescriber's directions and complete the full prescribed course.

Malarone is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk. Breastfeeding mothers should consult their physician, as the drug can be excreted in breast milk.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details and any necessary import documentation.

Malarone combines atovaquone and proguanil, offering a synergistic effect that provides both prophylaxis and treatment with a relatively favorable safety profile. Compared with older agents such as chloroquine or mefloquine, it has fewer neuropsychiatric side effects and retains activity against many chloroquine‑resistant strains, though cost may be higher.

Malarone tablets should be stored at temperatures below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Malarone is taken orally with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, taken daily throughout the stay, and continued for 7 days after leaving. For treatment, the dosing schedule is prescribed by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations indicating hepatotoxicity, hypersensitivity reactions that may lead to anaphylaxis, and rare hemolytic anemia. Patients should seek immediate medical attention if they develop rash, jaundice, fever, or unexplained bruising.

Malarone should be avoided in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should not be used concurrently with drugs that have major interactions, such as rifampin or cimetidine, without medical supervision.